natgillin/translations-raw huggingface dataset:
Resistance outcomes, including cross resistance to other NNRTIs, in patients receiving rilpivirine hydrochloride in combination with emtricitabine/tenofovir disoproxil fumarate in Phase III studies (C209 and C215 pooled data) and experiencing virological failure, are shown in Table 3 below.
Tablica 3 niže prikazuje ishode rezistencije, uključujući križnu rezistenciju na druge NNRTI-eve, u pacijenata koji su primali rilpivirinklorid u kombinaciji s emtricitabinom/tenofovirdizoproksilfumaratom u III fazi ispitivanja (objedinjeni podaci iz ispitivanja C209 i C215), u kojih je nastupio virološki neuspjeh.
Resistance to antibiotics
rezistencija na antibiotike
resistance to atazanavir (see
rezistencije na atazanavir (vidjeti dio 4.4).
Resistance to azole antifungals is most commonly exhibited by modification of the cyp51A gene which encodes for the target enzyme 14-alpha-sterol demethylase.
Rezistentnost na azolne antimiotike često je ispoljena modifikacijom cyp51A gena koji kodira ciljni enzim sterol 14-alfa demetilazu.
Resistance to cephalosporins results from enzymatic inactivation (-lactamase production) or from other mechanisms.
Otpornost na cefalosporine uzrokovana je enzimskom inaktivacijom (proizvodnja -laktamaze) ili drugim mehanizmima.
Resistance to cephalosporins results from enzymatic inactivation (-lactamase production), from reduced permeability by porin mutations or change in efflux, or by selection of low-affinity penicillin-binding proteins.
Otpornost na cefalosporine uzrokovana je enzimskom inaktivacijom (proizvodnja -laktamaze), od smanjene propusnosti mutacijama porina ili promjene u efluksu, ili selekcijom proteina sa niskim afinitetom vezanja na penicilin.
Resistance to dalbavancin in Staphylococcus spp. and Enterococcus spp. is mediated by VanA, a genotype that results in modification of the target peptide in nascent cell wall.
Rezistencija na dalbavancin kod Staphylococcus spp. i Enterococcus spp. posredovana je s VanA, genotipom koji rezultira modifikacijom ciljnog peptida u nastajućoj staničnoj stijenci.
Resistance to delamanid has occurred during treatment.
Rezistencija na delamanid pojavila se tijekom liječenja.
Resistance to efavirenz
Rezistencija na efavirenz
Resistance to emtricitabine or tenofovir has been seen in vitro and in some HIV-1 infected patients due to the development of an M184V or M184I substitution in RT with emtricitabine or a K65R substitution in RT with tenofovir.
Rezistencija na emtricitabin ili tenofovir opažena je in vitro te u nekih pacijenata koji su inficirani virusom HIV-1 uslijed razvoja supstitucije RT na položaju M184V ili M184I kod emtricitabina ili supstitucije RT na položaju K65R kod tenofovira.
Resistance to emtricitabine or tenofovir has been seen in vitro and in some HIV-1 infected patients due to the development of the M184V or M184I substitution in RT with emtricitabine, or the K65R substitution in RT with tenofovir.
Rezistencija na emtricitabin ili tenofovir ustanovljena je in vitro te u nekih pacijenata inficiranih virusom HIV-1 zbog razvoja supstitucije M184V ili M184I u RT s emtricitabinom ili supstitucije K65R u RT s tenofovirom.
Resistance to emtricitabine or tenofovir has been seen in vitro and in the HIV-1 from some patients due to the development of the M184V or M184I emtricitabine resistance substitution in reverse transcriptase or the K65R tenofovir resistance substitution in reverse transcriptase.
Rezistencija na emtricitabin i tenofovir bila je opažena in vitro i u nekih pacijenata inficiranih virusom HIV-1, zbog razvoja M184V ili M184I supstitucije rezistencije na emtricitabin u reverznoj transkriptazi ili K65R supstitucije rezistencije na tenofovir u reverznoj transkriptazi.
Resistance to emtricitabine/lamivudine
Rezistencija na emtricitabin/lamivudin
Resistance to emtricitabine/lamivudine (M184I/V)
Rezistencija na emtricitabin/lamivudin (M184I/V)
Resistance to fluoroquinolones has been reported to arise from five sources, (i) point mutations in the genes encoding for DNA gyrase and/or topoisomerase IV leading to alterations of the respective enzyme, (ii) alterations of drug permeability in Gram-negative bacteria, (iii) efflux mechanisms, (iv)plasmid mediated resistance and (v) gyrase protecting proteins.
Otpornost na fluorokinolone zabilježena je da proizlazi iz pet izvorišta, (i) točke mutacije na genima koji kodiraju DNA girazu i/ili topoizomerazu IV što dovodi do promjena dotičnih enzima, (ii) promjene permeabilnosti kod Gram-negativnih bakterija, (iii) protočni mehanizmi, (iv) otpornost posredovana plazmidima i ( v) proteini čuvari giraze.
Resistance to lopinavir, defined as the presence of any primary or active site mutations in protease (see above), was observed in 0/51 (0%) patients.
Rezistencija na lopinavir, definirana kao prisustvo bilo kojeg primarnog ili aktivnog mjesta mutacije u proteazi (vidjeti gore) je zabilježena kod 0/51 (0%) bolesnika.
Resistance to macrolides can develop by mutations in genes encoding ribosomal RNA (rRNA) or some ribosomal proteins; by enzymatic modification (methylation) of the 23S rRNA target site, generally giving rise to cross-resistance with lincosamides and group B streptogramins (MLSB resistance); by enzymatic inactivation; or by macrolide efflux.
Otpornost na makrolide može se razviti mutacijom u genima koji kodiraju ribosomsku RNK (rRNK) ili neke ribosomske proteine; enzimskom modifikacijom (metilacijom) ciljnog mjesta 23S rRNK, što općenito pobuđuje križnu otpornost s linkozamidima i streptograminima skupine B (MLSB otpornost); enzimskom inaktivacijom; ili makrolidnim efluksom.
Resistance to macrolides generally results from three mechanisms: (1) the alteration of the ribosomal target site (methylation), often referred to as MLSB resistance as it affects macrolides, lincosamides and group B streptogramins; (2) the utilisation of active efflux mechanism; (3) the production of inactivating enzymes.
Otpornost na makrolide općenito rezultira iz 3 mehanizma: (1) promjena ribosomskog ciljnog mjesta (metilacija), često se spominje kao rezistencija na MLSB jer utječe na makrolide, likozamide i skupinu B streptogramine, (2) korištenje aktivnog mehanizma istjecanja, (3) proizvodnja inaktivirajućih enzima.
Resistance to paritaprevir and ombitasvir conferred by variants in NS3 and NS5A respectively, selected in cell culture or identified in Phase 2b and 3 clinical trials were phenotypically characterised in the appropriate genotype 1a or 1b replicons.
Rezistencija na paritaprevir i ombitasvir odnosno rezistencija uzrokovana varijantama u proteinima NS3 ili NS5A izdvojenima u staničnoj kulturi ili identificiranima u kliničkim ispitivanjima faze 2b i 3, bila je fenotipski okarakterizirana u odgovarajućim replikonima genotipa 1a ili 1b.
Resistance to rilpivirine
Rezistencija na rilpivirin
Resistance to rilpivirine
Rezistencija# na emtricitabin/lamivudin
Resistance to rilpivirine2 Cross resistance3 to etravirine efavirenz nevirapine
Rezistencija na rilpivirin2 Križna rezistencija3 na etravirin efavirenz nevirapin
Resistance to tenofovir (K65R)
Rezistencija na tenofovir (K65R)
Resistance to tylvalosin by Mycoplasma hyopneumoniae and Lawsonia intracellularis has not been reported or found in the field to date.
Do sada nije zabilježena ili ustanovljena rezistencija bakterija Mycoplasma hyopneumoniae i Lawsonia intracellularis na tilvalozin.
Resistance# to emtricitabine/lamivudine
Rezistencija# na emtricitabin/lamivudin
Resistance-associated variants at amino acid positions R155 and D168 in NS3 were rarely observed (less than 1%) at baseline.
Varijante na aminokiselinskim položajima R155 i D168 u NS3, povezane s rezistencijom, rijetko su primijećene (u manje od 1% slučajeva) na početku ispitivanja.
resistance.
uzrokuje
Resistance: HIV-1 resistance to emtricitabine develops as the result of changes at codon 184 causing the methionine to be changed to a valine (an isoleucine intermediate has also been observed) of the HIV reverse transcriptase.
Rezistencija: Rezistencija virusa HIV-1 na emtricitabin razvija se kao rezultat promjena kodona 184 koje uzrokuju promjenu metionina u valin (opažen je i posrednik izoleucin) reverzne transkriptaze HIV-a.
Resistance: No HBV mutations associated with tenofovir disoproxil fumarate resistance have been identified (see Clinical efficacy and safety).
Rezistencija: Nisu zabilježene mutacije virusa HBV povezane s rezistencijom na tenofovirdizoproksilfumarat (vidjeti Klinička djelotvornost i sigurnost).
Resistance: Strains of HIV-1 with reduced susceptibility to tenofovir and a K65R mutation in reverse transcriptase have been selected in vitro and in some patients (see Clinical efficacy and safety).
Rezistencija: Sojevi HIV-1 smanjene osjetljivosti na tenofovir i s mutacijom reverzne transkriptaze K65R bili su izdvojeni in vitro i u nekih pacijenata (vidjeti odlomak Klinička djelotvornost i sigurnost).
Resistant (R>)
Rezistentni (R>)
resistant capsules)
(20 mg tvrde želučanootporne kapsule)
resistant capsules)
želučanootporne kapsule)
Resistant to FPV/RTV
Otporni na FPV/RTV
Resistant to Prior TKI Therapy a *, n (%)
Rezistentni na prethodnu TKI terapijua *, n(%)
Resistant to Prior TKI Therapy a *, n (%)
Rezistentni na prethodnu TKI terapijua*, n(%)
Reslizumab clearance is approximately 7 mL/hour.
Klirens reslizumaba približno je 7 ml/sat.
Reslizumab is a humanised monoclonal antibody produced in mouse myeloma cells (NS0) by recombinant DNA technology.
Reslizumab je humanizirano monoklonsko protutijelo proizvedeno u stanicama mijeloma miša (NS0) pomoću tehnologije rekombinantne DNK.
Reslizumab produced significant reductions in asthma exacerbations relative to placebo in the refractory population (59%) and non-refractory population (49%).
U populaciji s refraktornom (59 %) i onoj s nerefraktornom (49 %) bolešću reslizumab je značajno smanjio egzacerbacije astme u odnosu na placebo.
Resolor 1 mg film-coated tablets are white to off-white round shaped tablets marked “PRU 1” on one side.
Resolor 1 mg filmom obložene tablete bijele su do bjelkaste, okrugle tablete s oznakom “PRU 1” na jednoj strani.
Resolor can be taken with or without food and drinks, at any time of the day.
Resolor se može uzimati s hranom i pićem ili bez njih, u bilo koje doba dana.
Resolor is not recommended during pregnancy.
Resolor se ne preporučuje tijekom trudnoće.
Resolor may have a minor influence on the ability to drive and use machines, since dizziness and fatigue have been observed in clinical studies, particularly during the first day of treatment (see section 4.8).
Resolor može imati manji utjecaj na sposobnost upravljanja vozilima i rada sa strojevima, budući da su u kliničkim ispitivanjima opažene omaglica i umor, osobito tijekom prvog dana liječenja (vidjeti dio 4.8).
Resolor with food and drink
Resolor s hranom i pićem
Resolution occurred in 116 patients (92.8%) with a median time to resolution of 5.0 weeks (range: 0.1-53.1).
Nuspojave su se povukle u 116 bolesnika (92,8%), a medijan vremena do njihova povlačenja iznosio je 5,0 tjedana (raspon: 0,1-53,1).
Resolution occurred in 17 patients (89.5%) with a median time to resolution of 1.9 weeks (range: 0.4- 42.6+).
Nuspojave su se povukle u 17 bolesnika (89,5%), a medijan vremena do njihova povlačenja iznosio je 1,9 tjedana (raspon: 0,4-42,6+).
Resolution occurred in 184 patients (90.6%) with a median time to resolution of 3.0 weeks (range: 0.1-78.7+).
Nuspojave su se povukle u 184 bolesnika (90,6%), a medijan vremena do njihova povlačenja iznosio je 3,0 tjedana (raspon: 0,1-78,7+).
Resolution occurred in 19 patients (83%) with a median time to resolution of 2.0 weeks (range: 0.1-31.0).
Nuspojave su se povukle u 19 bolesnika (83%), a medijan vremena do njihova povlačenja iznosio je 2,0 tjedna (raspon: 0,1-31,0).
Resolution occurred in 192 patients (67.6%) with a median time to resolution of 10.4 weeks (range: 0.1-74.0+).
Nuspojave su se povukle u 192 bolesnika (67,6%), a medijan vremena do njihova povlačenja iznosio je 10,4 tjedna (0,1-74,0+).
Resolution occurred in 207 patients (89%) with a median time to resolution of 2.1 weeks (range: 0.1-88.3+).
Nuspojave su se povukle u 207 bolesnika (89%), a medijan vremena do njihova povlačenja iznosio je 2,1 tjedan (raspon: 0,1-88,3+).
Resolution occurred in 295 patients (62%) with a median time to resolution of 18.1 weeks (0.1- 113.7+).
Nuspojave su se povukle u 295 bolesnika (62%), a medijan vremena do njihova povlačenja iznosio je 18,1 tjedan (0,1-113,7+).
Resolution occurred in 47 patients (84%) with a median time to resolution of 5.3 weeks (range: 0.6-53.1+); + denotes a censored observation.
Nuspojave su se povukle u 47 bolesnika (84%), a medijan vremena do njihova povlačenja iznosio je 5,3 tjedna (raspon: 0,6-53,1+); + označava cenzurirano opažanje.
Resolution occurred in 6 patients (50%) with a median time to resolution of 20.6 weeks (0.4-47.6+); + denotes a censored observation.
Nuspojave su se povukle u 6 bolesnika (50%), a medijan vremena do njihova povlačenja iznosio je 20,6 tjedana (raspon: 0,4-47,6+);+ označava cenzurirano opažanje.
Resolution occurred in 74 patients (45%) with a median time to resolution of 66.6 weeks (0.4-96.1+).
Nuspojave su se povukle u 74 bolesnika (45%), a medijan vremena do njihova povlačenja iznosio je 66,6 tjedana (0,4-96,1+).
Resolution occurred in 95 patients (79%) with a median time to resolution of 5.1 weeks (range: 0.1-82.6+).
Nuspojave su se povukle u 95 bolesnika (79%), a medijan vremena do njihova povlačenja iznosio je 5,1 tjedan (raspon: 0,1-82,6+).
resolved or healing is achieved.
bol, ne prestane ili se ne postigne cijeljenje.
Resolves to Grade 0, 1 or 2.
Povlači se na 0., 1. ili 2. stupanj.
Resolves to Grade 0-1 or baseline.
Povlači se na 0.-1. stupanj ili na početno stanje.
Resolves to less than 2 gm / 24 hours.
Povlači se na vrijednost manju od 2 gm / 24 sata.
Resorption bone increased*
Pojačana resorpcija kosti
Resources for the management of anaphylaxis or serious reactions should be available.
Moraju biti dostupni osoblje i oprema za liječenje anafilaksije ili ozbiljnih reakcija.
Resources for the management of hypersensitivity and/or anaphylactic reactions should be available.
Moraju biti dostupni osoblje i oprema za liječenje reakcija preosjetljivosti i/ili anafilaktičkih reakcija.
respect to efficacy and
obzirom na djelotvornost i
RESPIPORC FLU3 suspension for injection for pigs
RESPIPORC FLU3 injekcijska suspenzija za svinje.
Respiration abnormal, oropharyngeal pain, sinus congestion*, rhinorrhoea, pharyngeal erythema*
poremećeno disanje, orofaringealna bol, kongestija sinusa*, rinoreja, faringealni eritem
Respiration should be monitored in non-intubated patients due to the risk of respiratory depression and in some case apnoea (see section 4.8).
Kod neintubiranih bolesnika treba provoditi praćenje disanja zbog rizika od respiratorne depresije i, u nekim slučajevima, apneje (vidjeti dio 4.8).
Respiratory
Poremećaji dišnog sustava
respiratory
Često
Respiratory -related death
Smrti povezane s dišnim sustavom
Respiratory and cardiac symptoms such as bronchospasm, larynx and throat irritation, wheezing, laryngeal oedema and atrial fibrillation have also been reported (see section 4.4).
Također su prijavljeni respiratorni i srčani simptomi, poput bronhospazma, nadraženosti grkljana i grla, piskanja pri disanju, edema grkljana i fibrilacije atrija (vidjeti dio 4.4).
Respiratory and haemodynamic symptoms should be treated symptomatically.
Respiratorne i hemodinamske simptome treba liječiti simptomatski.
respiratory arrest
otkazivanje pluća
Respiratory arrest
respiracijski arest
Respiratory arrest
respiratorni arest
Respiratory arrest Apnea
zastoj disanja apneja
Respiratory depression may lead to respiratory acidosis and respiratory arrest (at sevoflurane concentrations of 2.0 MAC and above) in spontaneously breathing dogs.
Respiratorna depresija može dovesti do respiratorne acidoze i respiratornog aresta (pri koncentracijama sevoflurana od 2,0 MAC i višima) u pasa sa spontanim disanjem.
Respiratory depression Sleep apnoea syndrome
respiratorna depresija, sindrom apneje u snu
Respiratory depression, epistaxis, nasal ulcer, rhinorrhea
Respiratorna depresija, epistaksa, ulceracija nosa, rinoreja
respiratory disease, chest pain, dyspnoea, increased cough, rhinitis
bolest dišnog sustava, bol u prsima, dispneja, pojačan kašalj, rinitis
respiratory disease, suicide or hospitalisation for suicide attempt, and new
povezanih s respiratornim bolestima, suicida ili hospitalizacija
Respiratory disorder
poremećaj disanja
respiratory disorder, oropharyngeal pain, cough, dysphonia
respiratorni poremećaj, orofaringealna bol, kašalj, disfonija
Respiratory disorders
Poremećaji dišnog sustava
Respiratory disorders
Poremećaji dišnog sustava, prsišta i sredoprsja
respiratory disorders and inflammation (including asthma, shortness of breath, cough, blocked sinuses, pleurisy, or difficulty breathing)
poremećaji dišnog sustava i upala (uključujući astmu, nedostatak zraka, kašalj, začepljenje sinusa, upalu plućne ovojnice ili otežano disanje)
Respiratory disorders Cough.
Poremećaji dišnog sustava, prsišta i sredoprsja Kašalj.
Respiratory disorders, including dyspnoea (21%), cough (18%) and tachypnoea (13%) were very commonly reported, and two patients with pre-existing asthma developed mild to moderate respiratory distress associated with MEPACT treatment in a phase II study.
Poremećaji dišnog sustava, uključujući dispneju (21%), kašalj (18%) i tahipneju (13%) prijavljivani su vrlo često, a dva bolesnika s prethodno prisutnom astmom su u ispitivanju faze II razvila blage do umjerene smetnje disanja povezane s liječenjem lijekom MEPACT.
Respiratory disorders:
Poremećaji dišnog sustava
respiratory distress
respiratorni distres
Respiratory distress (including pneumonitis and pulmonary oedema)
Rijetko: Respiratorni distres (uključujući pneumonitis i plućni edem)
Respiratory distress Bronchospasm Wheezing Pharyngeal oedema Dyspnoea Tachypnoea
respiratorni distres bronhospazam piskanje pri disanju faringealni edem dispneja
Respiratory distress, Dyspnoea
Često respiratorni distres, dispneja
Respiratory distress, dyspnoea, cough
respiratorni distres, dispneja, kašalj
Respiratory distress, wheezing, cough, rhinitis, nasal congestion, sneezing
Respiratorni distres, zviždanje pri disanju, kašalj, rinitis, nazalna kongestija, kihanje
respiratory distress9
respiratorni distres9
Respiratory domain of Cystic Fibrosis Questionnaire - Revised (CFQ-R)
Dio koji se odnosi na respiraciju revidiranog Upitnika o cističnoj fibrozi (Cystic Fibrosis Questionnaire - Revised - CFQ- R)
Respiratory Drugs
Respiratorni lijekovi
Respiratory events (e.g., chest discomfort, dyspnoea, and respiration abnormal) were more common during initiation of lumacaftor/ivacaftor therapy.
Respiratorni događaji (npr. nelagoda u prsima, dispneja i poremećeno disanje) bili su češći za vrijeme započinjanja terapije lumakaftorom/ivakaftorom.
Respiratory events like dyspnoea and pulmonary oedema, particularly in association with concomitant administration of other medicinal products with tocolytic activity, like calcium antagonists and beta- mimetics, and/or in women with multiple pregnancy, have been reported post-marketing.
Nakon stavljanja lijeka u promet prijavljeni su događaji povezani s dišnim sustavom, poput dispneje i plućnoga edema, osobito kod istodobne primjene drugih lijekova s tokolitičkim djelovanjem, poput antagonista kalcija i beta-mimetika, i/ili u žena s višeplodnom trudnoćom.
Respiratory events like dyspnoea and pulmonary oedema, particularly in association with concomitant administration of other medicinal products with tocolytic activity, like calcium antagonists and beta- mimetics, and/or in women with multiple pregnancy, have been reported post-marketing.
U fazi nakon stavljanja u promet gotovog lijeka bilježe se dišne pojave poput dispneje i edema pluća, posebno u slučaju istovremene primjene drugih lijekova s tokolitičkom aktivnosti kao što su kalcijevi antagonisti i beta-mimetici, i/ili višeplodna trudnoća u žena.
Respiratory events like dyspnoea and pulmonary oedema, particularly in association with concomitant administration of other medicinal products with tocolytic activity, like calcium antagonists and beta- mimetics, and/or in women with multiple pregnancy, have been reported post-marketing.
U fazi nakon stavljanja u promet gotovog lijeka bilježe se respiratorni događaji poput dispneje i edema pluća, posebno u slučaju istovremene primjene drugih lijekova s tokolitičkom aktivnosti kao što su kalcijevi antagonisti i beta-mimetici, i/ili višeplodna trudnoća u žena.
Respiratory events such as shortness of breath or chest tightness were seen in patients when starting Orkambi.
Respiratorni događaji, kao što su nedostatak zraka ili stezanje u prsima, opaženi su u bolesnika kada su počeli uzimati Orkambi.
respiratory failure
zatajenje disanja
Respiratory failure, Acute respiratory distress syndrome, Apnoea, Pneumothorax, Atelectasis, Pulmonary hypertension, Haemoptysis, Hyperventilation, Orthopnoea, Pneumonitis, Respiratory alkalosis, Tachypnoea, Pulmonary fibrosis, Bronchial disorder*, Hypocapnia*, Interstitial lung disease, Lung infiltration, Throat tightness, Dry throat, Increased upper airway secretion, Throat irritation, Upper-airway cough syndrome
Respiracijska insuficijencija, akutni respiratorni distres sindrom, apneja, pneumotoraks, atelektaza, plućna hipertenzija, hemoptiza, hiperventilacija, ortopneja, pneumonitis, respiratorna alkaloza, tahipneja, plućna fibroza, bronhijalni poremećaj*, hipokapnija*, intersticijska bolest pluća, infitracija pluća, stezanje u grlu, suhoća grla, povećana sekrecija gornjih dišnih puteva, iritacija grla, sindrom gornjih dišnih puteva koji je uzrok kašlja
respiratory failure, acute respiratory distress syndromeb, lung infiltration, pulmonary oedema, pneumonitis, allergic rhinitis
respiratorno zatajenje, akutni respiratorni distres sindromb, infiltracija pluća, plućni edem, pneumonitis, alergijski rinitis
Respiratory failure, pneumonia aspiration
zatajenje disanja, aspiracijska pneumonija
respiratory failure.
zatajenje disanja;
respiratory failure4
Vrlo rijetko
respiratory failure4,
zatajenje dišnog sustava4
Respiratory failurea
respiratorno zatajenjea
respiratory failures, respiratory tract disorders, asthma
respiratorno zatajenje, poremećaji dišnih puteva, astma
respiratory infection
infekcija dišnih puteva
respiratory infection
infekcija dišnih putova
respiratory infection numbness
infekcija dišnih puteva utrnulost
respiratory infection, bronchitis
pneumonija, sinusitis, infekcija gornjih dišnih puteva, bronhitis
respiratory infections – such as of the nose, sinuses or throat
infekcije dišnog sustava – poput nosa, sinusa ili grla
Respiratory infections, bronchitis, coughing with phlegm, flu like illness
infekcije dišnog sustava, bronhitis, iskašljavanje sluzi, bolest nalik gripi
Respiratory insufficiency: treat with artificial respiration
respiratorna insuficijencija: liječiti umjetnom respiracijom
Respiratory reactions, including death due to bronchospasm in patients with asthma have been reported following administration of some ophthalmic beta-blockers.
Respiratorne reakcije, uključujući smrt uslijed bronhospazma kod bolesnika s astmom prijavljene su nakon primjene određenih oftalmoloških beta-blokatora.
Respiratory reactions, including death due to bronchospasm in patients with asthma have been reported following administration of some ophthalmic beta-blockers.
Respiratorne reakcije, uključujući smrt zbog bronhospazma kod bolesnika sa astmom zabilježene su nakon lokalne primjene u oko nekih beta blokatora.
respiratory response to carbon dioxide.
vrijednosti flutikazonpropionata u
Respiratory symptoms (dyspnoea) Respiratory symptoms (bronchospasm)
respiratorni simptomi (dispneja) respiratorni simptomi (bronhospazam)
Respiratory system bleedingsf
Krvarenja u dišnom sustavuf
Respiratory tract
Dišni sustav
respiratory tract
infekcija gornjih
Respiratory tract (sinuses, throat and chest) infection
infekcija dišnih puteva (sinusi, grlo i prsište)
Respiratory tract bleeding (haemoptysis, pulmonary haemorrhage), bronchospasm, interstitial pneumonitis
krvarenje u dišnome sustavu (hemoptiza, plućno krvarenje), bronhospazam, intersticijski pneumonitis, eozinofilna pneumonija